Today, the Senate is expected to begin consideration of S. 1519, the FY 2018 National Defense Authorization Act (NDAA). As reported by the Senate Armed Services Committee, S. 1519 would have negative impacts on U.S. Department of Defense medical research programs. The Children’s Tumor Foundation has actively and continuously engaged for the past months in many avenues of bipartisan advocacy to nullify these specific provisions in the legislation, working with the Foundation’s Capitol Hill allies, the Defense Health Research Consortium, and other stakeholders to ensure no impact to the Department of Defense medical research programs.
On Friday, May 5, President Donald Trump signed the $1 trillion omnibus spending bill into law. This measure, which passed both chambers of Congress with bipartisan support, funds the government through the end of September. Importantly, it provides $15 million in funding through the Congressionally Directed Medical Research Program - Neurofibromatosis Research Program (CDMRP-NFRP), which will support Children’s Tumor Foundation (CTF) work in NF research.
On Monday, May 1, House and Senate appropriators released text of a $1 trillion omnibus spending bill agreement to fund the government through the end of September. The agreement provides $15 million in funding through the Congressionally Directed Medical Research Program - Neurofibromatosis Research Program (CDMRP-NFRP).
Children's Tumor Foundation Fights for NF Research Funding in Our Nation's Capital
On Monday, February 27, Children’s Tumor Foundation President and Chief Scientific Officer Annette Bakker, PhD, and Vice President of Marketing and Communications Simon Vukelj advocated on Capitol Hill for continued funding of the Congressionally Directed Medical Research Programs (CDMRP) for neurofibromatosis research. They met with the staff of nine key Members of Congress who sit on the House Committee on Appropriations Subcommittee on Defense.
Foundation President and Chief Scientific Officer Annette Bakker Invited to Key Meeting Dedicated to Advancing Cures
NEW YORK, NY - June 29, 2016 - As top scientific leaders convene today in Washington, D.C. at the invitation of Vice President Joseph Biden, among them is Children’s Tumor Foundation President and Chief Scientific Officer Annette Bakker, PhD. The effort, called the National Cancer Moonshot Summit, is dedicated to shortening the length of time it takes to develop effective treatments for cancer in particular, and disease in general. The first-of-its-kind summit is focused on promoting collaboration among researchers, industry and patients, and to breaking down the barriers that hamper progress.